Chimera Research Group

previous arrow
next arrow

March 30th Biotech Update

The market continues higher albeit at a slower pace.  Clearly the epidemic is not getting any better so why is the market holding up relative well?  First, it could simply be the dead cat bounce from oversold conditions.  I suspect that most think that is the likely scenario and that is not necessarily wrong.  Second, […]

March 27th Biotech Update

Today is going to be an interesting day.  The news has not been good this week but the market has had a nice recovery.  I would expect that the news does not get any better this week and Boris Johnson has actually tested positive for COVID.  We open lower and it seems setup well for […]

March 25th Biotech Update

I am still trying to get setup at home.  I order a new desktop because I cannot stand writing on a laptop (I know I am a grumpy old man already).  In any case, I will try and get more notes out on this laptop even though it drives me a little crazy typing on […]

March 17 Biotech Update

Do we get our turn around Tuesday?  Timing is about right in terms of the oversold conditions and that they are almost historically oversold.  A true dead cat bounce would be absolutely epic in the short squeeze.  I am not talk a couple of percent or even 5%.  When the bounce happens it should be […]

Mailing List



Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.

Subscribe to Chimera Research Group and proceed with confidence.

Get Started

Recent Press


Log In

JoinLost Password?